Prospective Study of Growth Factor Concentrate Therapy for Treatment of Melasma.

Autor: Sthalekar B; Skin Smart Solutions Clinic, Mumbai, Maharashtra, India., Agarwal M; Department of Dermatology, Yavana Aesthetics Clinic, Mumbai, Maharashtra, India., Sharma V; Wockhardt Hospitals, Mumbai, Maharashtra, India., Patil CY; Wockhardt Hospitals, Mumbai, Maharashtra, India., Desai M; Wockhardt Hospitals, Mumbai, Maharashtra, India.
Jazyk: angličtina
Zdroj: Indian dermatology online journal [Indian Dermatol Online J] 2021 Jul 14; Vol. 12 (4), pp. 549-554. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).
DOI: 10.4103/idoj.IDOJ_750_20
Abstrakt: Background: Melasma is a common acquired pigmentary skin disorder. Currently, there are various treatment options available but none is effective universally.
Objective: Assess the role of Yuskin ® , a growth factor concentrate (GFC) therapy, a modified platelet rich plasma (PRP) technique for the treatment of melasma.
Materials and Methods: Subjects of Fitzpatrick skin type IV-V, of either gender, more than equal to 18 years of age, with a clinical diagnosis of melasma were enrolled in the study. Total three sessions of GFC monotherapy were given with one-month interval (day 0, day 30, and day 60) and follow up of subjects was done at day 90 for the final clinical assessment.
Results: Out of 40 subjects enrolled, 30 subjects completed three GFC sessions and 26, completed day 90 follow-up. Statistically significant decrease in the mean mMASI scores was observed at all visits compared to baseline ( P < 0.005 for each visit). Totally, 66.7% of severe melasma subjects showed improvement to mild to moderate category. Significant improvement in mean mMASI score was seen in subjects who had mild to moderate melasma at baseline ( P < 0.05). Overall, aesthetic improvement was reported in 88.5% of subjects. Side effects reported were mild such as injection site pain, erythema, oedema and bruising, and resolved spontaneously within a few hours to few days of onset.
Conclusion: Significant improvement in melasma was observed with GFC monotherapy, which needs further confirmation in larger randomized controlled studies. Overall, it was well tolerated. Thus, GFC therapy can be a safe, effective, and new option in the armamentarium of melasma management.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2021 Indian Dermatology Online Journal.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje